ID | 55305 |
JaLCDOI | |
フルテキストURL | |
著者 |
Naganuma, Atsushi
Department of Gastroenterology, Takasaki General Medical Center, National Hospital Organization
Hoshino, Takashi
Department of Gastroenterology, Takasaki General Medical Center, National Hospital Organization
Suzuki, Yuhei
Department of Gastroenterology, Takasaki General Medical Center, National Hospital Organization
Uehara, Daisuke
Department of Gastroenterology, Takasaki General Medical Center, National Hospital Organization
Kudo, Tomohiro
Department of Gastroenterology, Takasaki General Medical Center, National Hospital Organization
Ishihara, Hiroshi
Department of Gastroenterology, Takasaki General Medical Center, National Hospital Organization
Sato, Ken
Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine
Kakizaki, Satoru
Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine
Yamada, Masanobu
Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine
Takagi, Hitoshi
Department of Gastroenterology, Kusunoki Hospital
|
抄録 | The effect of skeletal muscle mass (SMM) on the outcomes of sorafenib treatment for hepatocellular carcinoma (HCC) has not been established. We measured the SMM in HCC patients treated with sorafenib, evaluated the patients’ survival, and evaluated the association between skeletal muscle depletion and sorafenib treatment. Of the 97 HCC patients treated with sorafenib at our institution in the period from July 2009 to February 2015, our study included 69 patients (51 males, 18 females) who had received sorafenib for ≥ 8 weeks and whose follow-up data were available. SMM was calculated from computed tomography images at the mid-L3 level (cm2) and normalized to height (m2) to yield the L3 skeletal muscle index (L3-SMI, cm2/m2). The median L3-SMI value was higher in the males (43 cm2/m2) compared to the females (36 cm2/m2). In the males only, the multivariate Cox regression identified an L3-SMI <43 cm2/m2 as independently associated with higher mortality compared to an L3-SMI ≥43 cm2/m2 (hazard ratio 2.315, 95% confidence interval: 1.125-4.765, p=0.023). Skeletal muscle depletion is a factor predicting poor prognosis for male patients with advanced HCC treated with sorafenib.
|
キーワード | skeletal muscle depletion
hepatocellular carcinoma
sorafenib
L3 skeletal muscle index
prognostic factor
|
Amo Type | Original Article
|
出版物タイトル |
Acta Medica Okayama
|
発行日 | 2017-08
|
巻 | 71巻
|
号 | 4号
|
出版者 | Okayama University Medical School
|
開始ページ | 291
|
終了ページ | 299
|
ISSN | 0386-300X
|
NCID | AA00508441
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
著作権者 | CopyrightⒸ 2017 by Okayama University Medical School
|
論文のバージョン | publisher
|
査読 |
有り
|
PubMed ID |